The effects of galantamine treatment on caregiver time in Alzheimer's disease
- 25 September 2003
- journal article
- clinical trial
- Published by Wiley in International Journal of Geriatric Psychiatry
- Vol. 18 (10) , 942-950
- https://doi.org/10.1002/gps.1000
Abstract
Aim: The aim of the study was to determine whether the clinical benefits of galantamine for patients with Alzheimer's disease lead to benefits for caregivers.Methods: Data were pooled from two concurrent, multi‐centre, randomized, double‐blind, placebo‐controlled, 6‐month trials. Time caregivers spent assisting with activities of daily living (ADL) and time patients could be left unsupervised each day were assessed using the Allocation of Caregiver Time Survey. In total, 825 patients with mild‐to‐moderate Alzheimer's disease were included.Results: At endpoint, caregivers of galantamine‐treated patients were more likely to report reductions (41% vs 37%), maintenance (19% vs 14%) or smaller increases (26% vs 34% reporting an increase >30 minutes) in time assisting with ADL compared with the placebo group (p = 0.026; Wilcoxon rank‐sum test). The mean daily time difference was 32 minutes (p = 0.011). Among patients with moderate Alzheimer's disease, caregivers of galantamine‐treated patients were even more likely to report reductions (46% vs 37%), maintenance (15% vs 6%) or smaller increases (25% vs 42% for increases >30 min) vs placebo (p = 0.004), with a mean daily time saving of 53 minutes (p = 0.021). Caregivers of galantamine‐treated patients were more likely to report increases (22% vs 18%), maintenance (45% vs 43%) or smaller reductions (30% vs 37% for reductions >30 minutes) in time the patient could be left unsupervised compared with placebo (p = 0.027). Mean daily time saving was 27 minutes. Among patients with moderate Alzheimer's disease, the treatment effect was greater (p = 0.029), with caregivers in the galantamine group reporting the change in time left unsupervised as 68 minutes longer each day than caregivers of patients receiving placebo.Conclusion: The clinical benefits of galantamine for patients with Alzheimer's disease are also associated with benefits to caregiving. Copyright © 2003 John Wiley & Sons, Ltd.Keywords
This publication has 31 references indexed in Scilit:
- Assessment of Health Economics in Alzheimer??s Disease (AHEAD)PharmacoEconomics, 2002
- Economic impact of Alzheimer's disease in the United KingdomThe British Journal of Psychiatry, 1999
- First International Pharmacoeconomic Conference on Alzheimerʼs Disease: Report and SummaryAlzheimer Disease & Associated Disorders, 1998
- Validity and Reliability of the Alzheimerʼs Disease Cooperative Study-Clinical Global Impression of ChangeAlzheimer Disease & Associated Disorders, 1997
- Models of Carers: How Do Social Care Agencies Conceptualise Their Relationship with Informal Carers?Journal of Social Policy, 1989
- Caregivers of the Frail Elderly: A National ProfileThe Gerontologist, 1987
- Evaluation of the Costs of Caring for the Senile Demented Elderly: A Pilot StudyThe Gerontologist, 1986
- Clinical diagnosis of Alzheimer's diseaseNeurology, 1984
- “Mini-mental state”Journal of Psychiatric Research, 1975